药物诱导的免疫媒介性脑膜炎:使用FAERS和JADER数据库进行现实世界药监测分析
Shanshan Xu1, Zhihui Song1, Yiman Li1
1Department of Pharmacy, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
BMJ open ophthalmology
|December 2, 2025
概括
这项研究分析了药物安全数据,以确定与免疫媒介性脑膜炎 (IMU) 相关的药物. 布罗卢齐祖马布,法里西马布和利法布丁显示出最强的关联,强调需要仔细监测高风险药物.
科学领域:
- 眼科医生 眼科 眼科
- 药物监督 药物监督 药物监督
- 药品安全 药品安全
背景情况:
- 免疫媒介性脑膜炎 (IMU) 是一种严重的眼部疾病.
- 识别与IMU相关的药物对于患者安全至关重要.
- 大规模的药监数据为药物诱导的不良事件提供了洞察力.
研究的目的:
- 通过使用大规模的药监数据,分析与药物相关的免疫媒介性脑膜炎 (IMU) 风险.
- 确定与IMU有显著关联的特定药物.
- 评估与不同药物类别相关的IMU的发病时间 (TTO).
主要方法:
- 使用FDA不良事件报告系统 (FAERS) 和日本不良药事件报告 (JADER) 数据库 (2004年第一季度 - 2024年第四季度) 的回顾性药监测研究.
- 不成比例分析 (报告几率比率 - ROR,信息组件 - IC) 以确定药物-IMU关联.
- 与药物相关的IMU的时间到发病 (TTO) 分析.
主要成果:
- 在FAERS和JADER中发现了超过19,000个IMU病例.
- 在女性中,IMU的患病率更高;30-80岁的年龄组受影响最多.
- 在IMU中,最强烈的药物关联是:布罗卢齐祖马布 (brolucizumab),法里西马布 (faricimab) 和里法布丁 (rifabutin).
- 抗瘤,免疫调节,感官器官和抗感染剂是经常关联的药物类别.
- 在药物类别中观察到TTO的显著差异.
结论:
- 一系列不同的药物都与IMU的发生或进展有关.
- 早期风险评估,监测和干预对于高风险药物至关重要.
- 为了更安全的治疗策略,需要对机制和风险因素进行进一步的研究.
相关概念视频
01:19Pharmacovigilance
1.6K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.6K
01:29Therapeutic Drug Monitoring: Affecting Factors
182
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
182
01:16Therapeutic Drug Monitoring: Overview and Classification
275
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
275
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
164
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
164
01:27Allergic Drug Reactions
1.3K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.3K
01:13Bioequivalence studies: Biowaivers
210
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
210